Reshma Singh
Executive Director - Translational Science Lead, Immunology Cell Therapy AstraZeneca
Seminars
Thursday 26th March 2026
Understanding of B-Cell Biology & Reset with a CD19/BCMA Dual Targeting CART in SLE/LN
10:00 am
- B cell depletion and reconstitution following dual CD19/BCMA CART targeting in SLE/LN
- Phenotypes of B cells pre-treatment and post-reconstitution.
- Potential comparison to other B cell targeting therapies
Thursday 26th March 2026
Panel Discussion: Making Cell Therapy for Autoimmunity an Off-the-Shelf Treatment Through the Advancement of Allogeneic & In Vivo Cell Therapies
11:30 am
Join this session for a candid conversation with experts pursuing the reality of of-the-shelf cell therapies:
- Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
- Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
- Deep diving into current indications being explored for allogeneic cell therapy
